Nabriva Therapeutics plc
NBRVF
$0.0001
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -75.60% | -5.36% | 14.15% | 3.28% | 11.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -75.60% | -5.36% | 14.15% | 3.28% | 11.50% |
| Cost of Revenue | 18.93% | -16.21% | 204.19% | 13.85% | 26.17% |
| Gross Profit | -1,321.76% | 59.98% | -893.08% | -51.11% | -55.98% |
| SG&A Expenses | -62.82% | -61.40% | -33.67% | -2.85% | -14.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.17% | -45.53% | 48.58% | 3.45% | -0.18% |
| Operating Income | -15.63% | 73.40% | -73.32% | -3.59% | 8.64% |
| Income Before Tax | -12.84% | 24.12% | -71.30% | -0.83% | 4.12% |
| Income Tax Expenses | -- | -- | 672.22% | 306.35% | -36.47% |
| Earnings from Continuing Operations | -8.92% | 26.39% | -74.37% | -8.09% | 5.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.92% | 26.39% | -74.37% | -8.09% | 5.79% |
| EBIT | -15.63% | 73.40% | -73.32% | -3.59% | 8.64% |
| EBITDA | -16.31% | 73.40% | -74.29% | -4.03% | 8.60% |
| EPS Basic | 14.72% | 45.93% | -24.45% | 20.06% | 39.55% |
| Normalized Basic EPS | 11.65% | 78.86% | -22.26% | 25.43% | 38.48% |
| EPS Diluted | 14.72% | 45.93% | -24.41% | 20.06% | 39.55% |
| Normalized Diluted EPS | 11.65% | 78.86% | -22.26% | 25.43% | 38.48% |
| Average Basic Shares Outstanding | 27.72% | 36.13% | 40.11% | 35.21% | 55.85% |
| Average Diluted Shares Outstanding | 27.72% | 36.13% | 40.11% | 35.21% | 55.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |